RxDoctor Payments Data

Steven Kessel, MD

Cardiovascular Disease · Palm Beach Gardens, FLNPI 1912941345

Payments from drug & device makers

$11,882in general payments, 2019–2025

Across 654 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • AstraZeneca$709
  • Boehringer Ingelheim$664
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$11,840100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,882 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$657,257
Medicare patients
1,685
Services billed
7,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$527,869
XareltoRivaroxaban200$232,888
Repatha SureclickEvolocumab212$169,643
CamzyosMavacamten12$92,327
EntrestoSacubitril/Valsartan78$88,276
JardianceEmpagliflozin53$45,104
VascepaIcosapent Ethyl35$34,937
OzempicSemaglutide13$27,232
MultaqDronedarone Hcl12$21,322
Repatha SyringeEvolocumab30$16,487
LivaloPitavastatin Calcium11$10,512
FarxigaDapagliflozin Propanediol15$9,886
Metoprolol Succinate570$8,513
Atorvastatin Calcium770$8,505
Ezetimibe391$8,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$523$527,869596 claims
Johnson & JohnsonXarelto$1,083$232,888200 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,174$92,32712 claims
NovartisEntresto$2,116$88,27678 claims
Boehringer IngelheimJardiance$664$45,10453 claims
Novo NordiskOzempic$192$27,23213 claims
Sanofi-aventis U.S. LLCMultaq$276$21,32212 claims
Kowa Pharmaceuticals America, Inc.Livalo$175$10,51211 claims
AstraZenecaFarxiga$709$9,88615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →